What Spravato Treatment Actually Looks Like in Orange County, From First Call to First Dose

At Resiliency Mind + Body Medicine, Spravato treatment starts with a single phone call or online inquiry, moves through an insurance check and a clinical evaluation, and typically reaches a first dose once a patient’s history confirms treatment-resistant depression and insurance coverage is in place. The evaluation itself is not a commitment to treatment. It’s where a provider determines whether Spravato, Deep TMS, or medication management fits a patient’s history. Once treatment begins, every dose is administered on-site under the FDA-mandated Spravato REMS Program, with a required two-hour monitoring period before a patient leaves.

Here is what that path looks like, step by step, for patients at the Newport Beach and San Juan Capistrano offices.

What Happens When You First Call About Spravato?

Most patients reach Resiliency one of two ways: filling out an online inquiry form after finding the practice through a search or a referral, or calling the Newport Beach office directly. A phone call is usually the faster path, since it lets the care team start identifying whether Spravato is worth discussing before any paperwork begins.

That first conversation covers the basics: what esketamine is, how it differs from an antidepressant pill, what the practice’s two Orange County locations offer, and what insurance verification will involve. It is not a diagnosis, and it is not a sales pitch.

Resiliency does not offer a free standalone evaluation for Spravato. Because the practice is insurance-based, the initial evaluation is billed like any other psychiatric visit, with the patient responsible for whatever co-pay their plan sets. A provider, not a sales team, makes the call on whether Spravato fits.

Because Spravato involves a controlled medication, an in-office monitoring requirement, and an FDA risk program, most patients have real questions before they book anything. A short phone call lets the care team answer those questions: what the REMS monitoring period involves, whether sedation is dangerous, how the medication differs from recreational ketamine, before a patient decides whether to move forward with scheduling.

Those questions get answered on that first call, along with what a patient’s coverage looks like. As Dr. Stefani LaFrenierre, Resiliency’s founding psychiatrist, describes it:

“After you’ve talked to them about their history, explained how Spravato could help them, and then finally gone over their coverage and the copay assistance program, you can hear a hopefulness coming from them that translates to establishing care with our clinic. This is equally true for Medi-Cal patients who have a hard time finding an in-network provider, and whose insurance fully covers them for treatment and transportation if they meet criteria.”

A first call ends with scheduling, not a decision. Nobody commits to Spravato, Deep TMS, or any other treatment before an evaluation actually happens with a provider.

Patients with CalOptima or other Medi-Cal coverage go through the same first call. Resiliency is one of the few Orange County practices accepting CalOptima Health for Deep TMS and Spravato with prior authorization, so insurance type doesn’t change how the first conversation goes. It changes what happens next.

How Does Insurance Verification Work Before a Spravato Evaluation?

Spravato is FDA-approved for treatment-resistant depression, defined by the FDA and the European Medicines Agency as an inadequate response to at least two different antidepressants taken at an adequate dose for an adequate length of time. Researchers estimate at least 30% of people with depression meet that definition, and insurers use it as the bar for approving Spravato rather than covering it for every diagnosis of depression.

Before an evaluation is scheduled, Resiliency’s team verifies benefits directly with the patient’s plan: commercial insurance, Medicare, or CalOptima/Medi-Cal. Resiliency is in-network with CalOptima Health and handles the prior authorization process for Deep TMS and Spravato directly with the plan, which is not something every Orange County practice offers CalOptima members.

Insurance coverage for Spravato is never a blanket guarantee. Plans generally require documentation of prior antidepressant trials, a confirmed diagnosis, and REMS-certified administration before approving treatment, and coverage still depends on the individual plan. Resiliency’s front desk handles that verification before a patient is scheduled, so patients aren’t left coordinating paperwork between their psychiatrist and their insurer on their own.

If a plan initially denies coverage, the next step is usually an appeal built around the same documentation: prior antidepressant trials, symptom severity, and why Spravato is medically appropriate for that specific patient. That process takes time, which is part of why insurance verification starts before, not after, the evaluation.

What Actually Happens at a Spravato Evaluation Appointment?

A Spravato evaluation is a clinical appointment, not a procedure. A provider reviews current symptoms, past antidepressant trials (what was tried, for how long, and what happened), and relevant medical history, including factors that matter for esketamine specifically, such as blood pressure and any history of psychosis or substance use.

A psychiatric provider, not a technician or intake coordinator, conducts the evaluation itself. That’s deliberate. Deciding between Spravato, Deep TMS, and medication management is a clinical judgment, and Resiliency’s model keeps that judgment with the provider who will also be involved in whichever treatment follows.

The goal isn’t to confirm a predetermined plan. Someone who hasn’t yet tried an adequate course of oral antidepressants may be better served by medication management first; someone who has tried multiple treatments without relief may be a candidate for Spravato, Deep TMS, or both together. That determination happens during the evaluation, with a provider, not before it.

Patients also complete the REMS enrollment paperwork at this stage if Spravato looks appropriate, and ask whatever questions remain about scheduling, the in-office monitoring requirement, or cost. None of this commits a patient to starting treatment that day.

Evaluations are also where Resiliency’s Deep TMS and Spravato are reviewed side by side for patients who are genuinely unsure which option fits, a decision that depends on treatment history and logistics as much as diagnosis.

Patients who can bring a list of past medications, including names, approximate dates, and why each was stopped, tend to move through this step faster, though Resiliency’s team can help reconstruct that history from records when a patient can’t recall every detail.

An evaluation is a conversation, not a contract. Patients can leave an evaluation having decided medication management is the better next step, or that they want more time before starting Spravato. Either is a normal outcome, not a wasted appointment.

That transparency is deliberate, and it is built around what the practice is trying to offer patients in the first place. Dr. LaFrenierre explains:

“Our priority at Resiliency is offering hope when traditional treatments have not worked. We do this by being very transparent and thorough during the evaluation process, including discussion of how Spravato works and copay assistance options that we offer. Most patients feel incredibly supported by our team and our mission of hope and decide to establish care with us. This is especially true for Medi-Cal patients, who often struggle to even find an in-network provider. Medi-Cal is especially unique because it has no co-pays, and covers the mandatory rides needed during Spravato treatment days.”

What Does Spravato Prior Authorization Actually Involve?

Once a provider determines Spravato is appropriate, the practice submits a prior authorization request to the patient’s insurer. That request typically documents the qualifying diagnosis, the antidepressants already tried, current symptom severity, and why Spravato, administered under the FDA’s REMS Program, is the recommended next step.

Resiliency’s administrative team manages this process directly with the payer, including CalOptima, rather than asking patients to track down their own authorization. Timelines vary by plan: some insurers respond within days, others take longer, and a plan can also request additional documentation before approving coverage.

This is also where the earlier evaluation pays off. A thorough first evaluation, with a clear record of past antidepressant trials and symptom history, gives the authorization request everything a reviewer needs the first time, which is part of why that initial visit covers so much ground.

Patients are not scheduled for a first dose until authorization (or, for self-pay patients, a confirmed payment arrangement) is in place. That sequencing exists for a practical reason: a REMS-certified treatment session requires real commitment of time from both the patient and the clinical team, and nobody wants to start that process only to have a session cancelled over a paperwork gap.

Patients who are ready to start this process can call Resiliency’s main line at (949) 996-5355 or submit an inquiry through the practice’s contact page to begin insurance verification.

What Happens During a First Spravato Dose?

On treatment days, Spravato is self-administered as a nasal spray under direct observation in a private treatment room, not injected and not taken at home. Vital signs are checked before dosing, and a clinical team member remains present throughout the appointment.

After the dose, the FDA’s Spravato REMS Program requires a minimum two-hour monitoring period before a patient is cleared to leave. Because dissociation and sedation are both possible effects, patients are not permitted to drive themselves home on treatment days. Someone else needs to handle transportation, or a patient arranges a rideshare in advance. CalOptima/Medi-Cal members who meet criteria may have transportation to and from treatment covered by their plan, which is worth asking about during benefits verification.

Resiliency reports an 80% treatment response rate across Deep TMS and Spravato combined, tracked using validated instruments including the PHQ-9 and GAD-7 across more than 7,000 completed treatments, published outcomes rather than a guarantee for any individual patient, since response depends on diagnosis, treatment history, and adherence to the full course.

A typical Spravato course starts with twice-weekly dosing for the first several weeks, with a provider reassessing symptoms at regular intervals to decide whether to continue, adjust, or stop. Patients already in medication management at Resiliency can usually continue that care alongside Spravato, rather than switching providers partway through treatment.

The most common effects during the two-hour window are temporary: drowsiness, dizziness, or a sense of disconnection that resolves before a patient is cleared to leave. Resiliency’s team monitors for these directly rather than leaving a patient alone with a form to fill out, which is part of what the concierge-style model is built around.

For patients coming from San Juan Capistrano or further into Orange County, the time commitment of the monitoring period is worth planning around: blocking out closer to three hours total once travel and check-in are factored in, rather than treating it as a quick in-and-out visit.

What Happens After the First Few Weeks of Spravato Treatment?

Spravato treatment runs in phases, not a fixed number of visits decided upfront. The first phase, often called induction, typically runs about four weeks with dosing twice a week. At the end of that initial period, a provider reassesses symptoms against where the patient started to decide whether to continue, adjust the dose, or stop.

Patients who respond well during induction usually move into a maintenance phase, where dosing frequency drops, often to once a week and then every other week, depending on how symptoms hold. This isn’t automatic. It’s a decision a provider makes at each reassessment, based on the same symptom tracking used throughout treatment.

Patients who don’t see meaningful improvement during induction have that conversation too. A provider reassessing at four weeks might recommend adjusting the Spravato dose, adding or changing an oral antidepressant, or reconsidering whether Deep TMS or another approach is a better fit. Spravato is not a one-way commitment. It’s meant to be reassessed on the same schedule it’s delivered.

Reassessment visits are shorter than the initial evaluation but follow the same logic: current symptoms compared against where a patient started, using the same validated rating scales used throughout treatment. Patients who started on a Newport Beach schedule or a San Juan Capistrano schedule generally continue at the same location, since the clinical team, the equipment, and the patient’s treatment history are already established there.

Throughout every phase, insurance stays part of the picture. Plans that authorize Spravato for a set period, often tied to the induction phase, require reauthorization to continue into maintenance, which is one more reason Resiliency’s team stays involved in a patient’s coverage well past the first dose.

Frequently Asked Questions

Patients who want to find out whether Spravato fits their history can call (949) 996-5355 or reach out through Resiliency’s contact page. Insurance verification and scheduling begin from there.